| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Profile: Biomedica, Inc.
Posted on 06/25/2007 08:20:30 | Link | Post Comment
BioHealth Investor Company Directory Profile
BioMedica, Inc.
11622 El Camino Real 100
San Diego, CA 92130
Tel 858 677 6500
Fax 858.677.6505
BioMedica Inc, located in San Diego, California, is a wholly owned subsidiary of Oxford BioMedica plc (LSE: OXB), a UK based biotechnology company specializing in the development of novel gene-based therapeutics for the treatment of cancer, neurodegenerative diseases and other disorders with major unmet clinical needs.
BioMedica Inc is focused primarily on business development activities in North America and Asia and on management of the Company’s intellectual property.
Oxford BioMedica’s development pipeline includes two novel anti-cancer products, TroVax® and MetXia®, in clinical trials and gene therapy treatments in advanced preclinical studies for retinopathy, RetinoStat®, and for Parkinson’s disease, ProSavin®.
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
BioMedica, Inc.11622 El Camino Real 100
San Diego, CA 92130
Tel 858 677 6500
Fax 858.677.6505
BioMedica Inc, located in San Diego, California, is a wholly owned subsidiary of Oxford BioMedica plc (LSE: OXB), a UK based biotechnology company specializing in the development of novel gene-based therapeutics for the treatment of cancer, neurodegenerative diseases and other disorders with major unmet clinical needs.
BioMedica Inc is focused primarily on business development activities in North America and Asia and on management of the Company’s intellectual property.
Oxford BioMedica’s development pipeline includes two novel anti-cancer products, TroVax® and MetXia®, in clinical trials and gene therapy treatments in advanced preclinical studies for retinopathy, RetinoStat®, and for Parkinson’s disease, ProSavin®.
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
When I first started Day Trading I traded anything that [read more]
LearningMarkets.com - Fri Oct 03, 2008 03:14PM
Written by S. Wade Hansen Why Should You Care About O [read more]
Written by S. Wade Hansen Why Should You Care About O [read more]
<< My Home | TheMoneyBlogs Home